What's Fueling the US Biotech Rally: Data Expectations and Macro Momentum Behind Wednesday's After-Hours Surge

fork_in_the_road · 2025-12-22T14:19:10+00:00

U.S. biotech stocks surged in after-hours trading, driven by anticipation of upcoming data releases and a positive response to the Federal Reserve's recent rate cut. Notable gainers included Corbus Pharmaceuticals and Curis, while macro-driven momentum also lifted smaller firms like Agape ATP Corp. and Cue Biopharma.

fork_in_the_road

2025-12-22 14:19:10

Abstract generation in progress

U.S. biotech stocks experienced a remarkable surge during after-hours trading on Wednesday, with small-cap and micro-cap names leading the charge. The market action reflected a combination of near-term catalyst anticipation and broader momentum-driven buying across the sector, triggered largely by the Federal Reserve’s recent rate cut decision that reignited investor appetite for high-volatility equities.

Data-Driven Catalysts Leading the Charge

Several biotech names rallied ahead of imminent corporate announcements. Corbus Pharmaceuticals Holdings, Inc. (CRBP) emerged as a standout performer, climbing 12.76% after hours to $11.57 as investors positioned ahead of the company’s Phase 1a SAD/MAD study results for CRB-913, scheduled for release before market open on December 11, 2025. The anticipated data release followed by an 8:00 a.m. ET conference call generated substantial pre-market excitement.

Curis, Inc. (CRIS) also extended its rally during extended trading, rising 7.68% to $1.3999. The advance built on momentum from the company’s clinical data presentation at the 67th ASH Annual Meeting on December 9, where its frontline AML triplet study (CA-4948-104) findings attracted ongoing investor focus.

Macro-Driven Rotation in High-Beta Names

Beyond data catalysts, the broader Fed-driven risk-on sentiment fueled a recovery wave across beaten-down biotech names. Agape ATP Corp. (ATPC) surged an impressive 29.41% after hours to $0.088, despite the absence of company-specific developments. This move epitomized the speculative buying surge in micro-cap names following the central bank’s accommodative policy shift.

Similarly, Cue Biopharma, Inc. (CUE) posted a double-digit after-hours advance of 13.12% to $0.54, while Anebulo Pharmaceuticals, Inc. (ANEB) rebounded 8.37% to $2.33. Both gainers lacked fresh corporate news, underscoring the macro-driven nature of the rotation.

Skye Bioscience, Inc. (SKYE) completed the recovery pattern with a 7.02% after-hours gain to $1.22, reflecting the sector-wide uplift as capital rotated back into beaten-down small-cap biotechs.

Strategic Partnerships Driving Selective Strength

Cerus Corporation (CERS) advanced 3.17% after hours to $1.95 on the back of concrete corporate progress. The company announced a group purchasing agreement with Blood Centers of America (BCA), establishing distribution for its complete INTERCEPT product line. The agreement is designed to expand access to pathogen-reduction technologies across BCA’s nationwide network, providing Cerus with tangible commercial momentum distinct from pure sentiment-based moves.

The Wednesday action highlighted how U.S. biotech markets are currently responding to a dual-driver environment: immediate clinical readouts capturing investor positioning ahead of data releases, coupled with macro-policy tailwinds that have rekindled enthusiasm for speculative equities within the broader biotechnology sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.